Systemic Treatments and Switching Therapy in Atopic Dermatitis

EP: 1.JAK Inhibitors and Pathophysiology of Atopic Dermatitis

EP: 2.Oral JAK inhibitors and Their Use for Treatment of Atopic Dermatitis

EP: 3.Oral JAK Inhibitor Use in Atopic Dermatitis: Screening and Monitoring Patients

EP: 4.Long-term Safety Data for JAK Inhibitors in Atopic Dermatitis

EP: 5.Utilizing Long-Term Atopic Dermatitis Data in Clinical Practice

EP: 6.Data on Early Itch Relief with JAK Inhibitors in Atopic Dermatitis

EP: 7.Speed of Itch Relief in Atopic Dermatitis

Now Viewing

EP: 8.Systemic Treatments and Switching Therapy in Atopic Dermatitis

EP: 9.Treatment Expectations and Patient Conversations in Atopic Dermatitis

EP: 10.Switching from Biologics to JAK Inhibitors in Atopic Dermatitis: Clinical Data

EP: 11.Treatment Breaks and Rescue Treatments in Atopic Dermatitis

EP: 12.Switching patients to JAK Inhibitors in Atopic Dermatitis in Clinical Practice

EP: 13.Treatment Flexibility While on Abrocitinib in Atopic Dermatitis (JADE REGIMEN)

EP: 14.Future Outlook for Atopic Dermatitis Treatments

Video content above is prompted by the following:

1. Biologics and other systemic treatments have revolutionized the atopic dermatitis (AD) treatment landscape. What is the place of biologics in AD? Please share your impressions of efficacy and safety of biologics in AD.
2. What are some of the reasons to consider switching a patient from one systemic treatment to another systemic treatment?